Piper Sandler upped their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th.

Blue Trust Inc. reduced its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 42.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The ...

Boston Scientific Corporation BSX, despite industrywide macroeconomic upheavals, has been seeing strong growth momentum ...

Headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company (BDX) is a global leader in medical technology ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Piper Sandler analyst Jason Bednar maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $280.00.

The S&P 500 increased 12.8% in the same time frame. The collaboration between BD and Biosero could boost BDX's stock price in the long run by solidifying BD's position as a leader in innovative ...